Sure, here's the revised description without the link: --- Subscribe! Welcome, ladies and gentlemen. So what I'd like to do ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...

Want more charts like these? See our charts on the secrets of the jobless recovery, the richest 1 percent of Americans, and how the superwealthy beat the IRS. How Rich Are the Superrich? A huge share ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.